Τετάρτη 25 Απριλίου 2018

3 harms of EMS miscommunication and how to fix them

Communication is critical to ensure that emergency department resources are available and ready for your patient

from EMS via xlomafota13 on Inoreader https://ift.tt/2Hrr1uT
via IFTTT

Measuring Variation Across Dimensions of Integrated Care: The Maryland Medicaid Health Home Model

Abstract

Despite the proliferation of initiatives to integrate services for people with serious mental illness (SMI), measures of distinct dimensions of integration, such as spatial arrangement and care team expertise, are lacking. Such measures are needed to support organizations' assessment of progress toward integrated service delivery. We developed measures characterizing integration of behavioral, somatic, and social services to operationalize the integrated care dimensions conceived by the Agency for Healthcare Research and Quality. In a survey fielded to 46 Maryland Medicaid health homes (response rate: 96%) serving adults with SMI during 2015–2016, we found that these measures provided a useful description of variation across dimensions of integration.



from Health via xlomafota13 on Inoreader https://ift.tt/2KeeKrt
via IFTTT

Endoscopic Electrocautery Incisional Therapy as a Treatment for Refractory Benign Pediatric Esophageal Strictures

Background and Aim: Refractory esophageal strictures are rare conditions in pediatrics, and are often due to anastomotic, congenital, or caustic strictures. Traditional treatment options include serial dilation and surgical stricture resection; endoscopic intralesional steroid injections, mitomycin C, and externally removable stents combined with dilation have had variable success rates. Although not as widely used, endoscopic electrocautery incisional therapy (EIT) has been reported as an alternative treatment for refractory strictures in a small number of adult series. The aim of the study was to evaluate the safety and efficacy of EIT in a pediatric population with refractory esophageal strictures. Methods: A retrospective chart review was conducted on all patients who underwent EIT for esophageal strictures (May 2011–September 2017) at our tertiary-care referral center. A total of 57 patients underwent EIT. Procedural success was defined as no stricture resection, appropriate diameter for age, and fewer than 7 dilations within 24 months of first EIT session. This corresponded to the 90th percentile of the observed number of dilations in the data. All patients included in the study had at least 2-year follow-up. Results: A total of 133 EIT sessions on 58 distinct anastomotic strictures were performed on 57 patients (24 girls). The youngest patient to have EIT was 3 months old and 4.8 kg. There were 36 strictures that met the criteria for refractory stricture and 22 non-refractory (NR) strictures. The median number of dilations before EIT therapy was 8 (interquartile range [IQR]: 6–10) in the refractory group and 3 (IQR: 0–3) in the NR group. In the refractory group, 61% of the patients met the criteria for treatment success. The median number of dilations within 2 years of EIT in the refractory group was 2 (IQR: 0–4). In the NR group, 100% of the patients met criteria for success. The median number of dilations within 2 years of EIT in the NR was 1 (IQR: 0–2). The overall adverse event rate was 5.3% (7/133), with 3 major (2.3%) and 4 minor events (3%). Conclusions: EIT shows promise as an adjunct treatment option for pediatric refractory esophageal strictures and may be considered before surgical resection even in severe cases. The complication rate, albeit low, is significant, and EIT should only be considered by experienced endoscopists in close consultation with surgery. Further prospective longitudinal studies are needed to validate this treatment. Address correspondence and reprint requests to Michael A. Manfredi, MD, 300 Longwood Avenue Boston, MA 02132 (e-mail: Michael.Manfredi@childrens.harvard.edu). Received 19 October, 2017 Accepted 22 March, 2018 The authors report no conflicts of interest. © 2018 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology,

from Gastroenterology via xlomafota13 on Inoreader https://ift.tt/2HrNFDi
via IFTTT

Use of Infliximab Biosimilar Versus Originator in a Paediatric United Kingdom Inflammatory Bowel Disease Induction Cohort

Objectives: To summarize short-term effectiveness, safety, and cost of using infliximab biosimilar (IFX-B) drugs, (Inflectra™ and Remsima™) compared to originator infliximab (IFX-O) (Remicade®) in biologic naive pediatric inflammatory bowel disease in the United Kingdom. Methods: Prospective audit of patients starting anti-TNF therapy. Disease severity, response to treatment, and remission rate was measured by Pediatric Crohn's Disease Activity Index (PCDAI) and/or Physician Global Assessment (PGA). Results: Between March 2015 and February 2016, 278 patients (175 IFX-O, 82 IFX-B, and 21 Adalimumab) were started on anti-TNF therapy. This was compared with collected data on 398 patients started on IFX-O from 2011–15. At initiation, median PCDAI was 36 (20,48) (n = 42) in the IFX-O group and 28 (20,40) (n = 29) in the IFX-B group, (p = 0.08). Immunosuppression rates were similar: 150/175 (86%) for IFX-O and 65/82 (79%) for IFX-B (p > 0.05). Post induction, median PCDAI score was 5 (0,11) (n = 19) and 0 (0,8) (n = 15) in the IFX-O and IFX-B groups respectively (p = 0.35). There was no difference in response to treatment using PGA 85% (n = 28) in IFX-O group and 86% (n = 19) in IFX-B group (p > 0.05). Adverse events (AE) at initiation and post induction were not different between both groups (p > 0.05). Using conservative calculations, £875,000 would have been saved over a one-year period with universal adoption of biosimilars in patients who were instead treated with IFX-O. Conclusions: IFX-B is likely as effective as IFX-O in treating IBD in comparable pediatric populations. Sites should adopt infliximab biosimilar for new starts due to cost reduction with no difference in other parameters. Address correspondence and reprint requests to Professor Richard K. Russell, Consultant Paediatric Gastroenterologist, Royal Hospital for Children, 1345 Govan Road, Glasgow, G51 4TF (e-mail: richardrussell@nhs.net). Received 16 January, 2018 Accepted 14 April, 2018 Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.jpgn.org). Optional byline at editor's discretion: matched initial efficacy and safety, but with significant cost savings. Conflicts of interest RM has received consultation fees, research grants, or honorarium, from AbbVie, Janssen, Dr Falk, Tillott's pharma, 4D pharma, and Pfizer. MKHA declares that he received educational travel grants or consultation fees from Abbvie, MSD, Nutricia, and Dr Falk. JF is on the advisory board for Falk, scientific advisory board for Jansen, and has received support for travel and educational activity from Abbvie. AR has received consultation fees on advisory boards and educational/travel grants from Abbvie. SGM has received sponsorship for conferences from Abbvie. DCW has received consultancy fees from consultancy, lecture fees, and sponsorship to travel to meetings from Abbvie, consultancy fees from Takeda, and lecture fees from Falk. RKR has received consultation fees, research grants, or honorarium, from Nestlé, AbbVie, Takeda, Napp, Mead Johnson, Nutricia and Janssen. All other authors declare no conflicts of interest. © 2018 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology,

from Gastroenterology via xlomafota13 on Inoreader https://ift.tt/2qYEYoW
via IFTTT

Cutting-edge Treatment for Benign Pediatric Esophageal Strictures, a Step Forward, More to Go

No abstract available

from Gastroenterology via xlomafota13 on Inoreader https://ift.tt/2HrhYKe
via IFTTT

Worldwide variation in the dietary management of eosinophilic oesophagitis

No abstract available

from Gastroenterology via xlomafota13 on Inoreader https://ift.tt/2qZyB4I
via IFTTT

Bile Acids and the Gut Microbiome as Potential Targets for NAFLD Treatment

Semi-synthetic bile acid (BA) obeticholic acid (OCA), a potent farnesoid X receptor (FXR) agonist, exhibited beneficial effects on non-alcoholic fatty liver disease (NAFLD). However, OCA did not cause a resolution of non-alcoholic steatohepatitis (NASH). Here we discuss several prominent knowledge gaps in BA/FXR biology. Firstly, although many groups reported elevated serum BA levels, there are reports of decreased or normal serum BA levels in NAFLD, underlining the complexity of BA regulation by environmental and genetic factors. Secondly, conflicting data exist in animal studies regarding the effects of FXR signaling on obesity and associated metabolic abnormalities. Thirdly, it remains obscure how the gut microbiome and the BA pool interact and influence the pathogenesis of NAFLD. Lastly, it is not known how FXR mediated signaling interact with G protein-coupled bile acid receptor 1 mediated signaling. Answering these questions may lead to an improved pharmaceutical intervention for NAFLD targeting the FXR signaling pathway. Address correspondence and reprint requests to Lixin Zhu, Digestive Diseases and Nutrition Center, Department of Pediatrics, The State University of New York at Buffalo, 3435 Main Street, 422BRB, Buffalo, NY14214 (e-mail: lixinzhu@buffalo.edu); Susan S. Baker (e-mail: sbaker@upa.chob.edu) Received 7 August, 2017 Accepted 27 March, 2018 Conflict of Interest and Source of Funding: The authors declare that no conflict of interest exists. This work was supported by GEM Community of Excellence, the University at Buffalo (LZ) and the Tommy and Peter Fund, Inc., Buffalo, NY (SSB and LZ). © 2018 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology,

from Gastroenterology via xlomafota13 on Inoreader https://ift.tt/2HrhKCS
via IFTTT